Urine as a liquid allograft biopsy: emerging technologies for noninvasive monitoring in kidney transplantation

PURPOSE OF REVIEW: Long-term kidney allograft survival remains limited by immune and nonimmune injury, while conventional surveillance tools are constrained by delayed detection, limited specificity, or invasiveness. Urine provides an accessible window into the allograft, containing inflammatory mediators, cells, extracellular vesicles, nucleic acids, proteins, peptides, and metabolites reflecting intra-graft processes. RECENT FINDINGS: Over the past two decades, urinary biomarkers have evolved from single-analyte discovery to molecular signatures matched to kidney biopsy findings. Urinary CXCL9/CXCL10, urinary-cell mRNA, extracellular-vesicle transcriptomics, donor-derived cell-free DNA, proteomics, and metabolomics provide complementary measures of allograft injury and have demonstrated encouraging diagnostic performance. Although some remain limited by variable specificity, analytical standardization, reproducibility, or insufficient prospective validation, others have undergone multicenter validation, assay standardization, and progression toward clinical implementation. SUMMARY: Urinary biomarkers are unlikely to replace biopsy with a single universal test. Their greatest potential lies in context-specific applications, including risk stratification, surveillance, biopsy triage, differential diagnosis, prognostication, and treatment-response monitoring. High negative predictive value across several platforms may support reducing unnecessary biopsies. Clinical translation will depend on standardized, transferable assays, external validation in representative populations, clearly defined contexts of use, and evidence that biomarker-guided strategies improve patient and allograft outcomes.

Authors

Institutions

Publication Details

Journal
Current Opinion in Nephrology & Hypertension
Published
2026-11-16
DOI
https://doi.org/10.1097/mnh.0000000000001242
Primary Topic
Renal Transplantation Outcomes and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Urine as a liquid allograft biopsy: emerging technologies for noninvasive monitoring in kidney transplantation

Rania El Fekih, Enver Akalin
1 links
Current Opinion in Nephrology & Hypertension
Renal Transplantation Outcomes and Treatments
article

Urine as a liquid allograft biopsy: emerging technologies for noninvasive monitoring in kidney transplantation

Rania El Fekih, Enver Akalin
article en

Abstract

PURPOSE OF REVIEW: Long-term kidney allograft survival remains limited by immune and nonimmune injury, while conventional surveillance tools are constrained by delayed detection, limited specificity, or invasiveness. Urine provides an accessible window into the allograft, containing inflammatory mediators, cells, extracellular vesicles, nucleic acids, proteins, peptides, and metabolites reflecting intra-graft processes. RECENT FINDINGS: Over the past two decades, urinary biomarkers have evolved from single-analyte discovery to molecular signatures matched to kidney biopsy findings. Urinary CXCL9/CXCL10, urinary-cell mRNA, extracellular-vesicle transcriptomics, donor-derived cell-free DNA, proteomics, and metabolomics provide complementary measures of allograft injury and have demonstrated encouraging diagnostic performance. Although some remain limited by variable specificity, analytical standardization, reproducibility, or insufficient prospective validation, others have undergone multicenter validation, assay standardization, and progression toward clinical implementation. SUMMARY: Urinary biomarkers are unlikely to replace biopsy with a single universal test. Their greatest potential lies in context-specific applications, including risk stratification, surveillance, biopsy triage, differential diagnosis, prognostication, and treatment-response monitoring. High negative predictive value across several platforms may support reducing unnecessary biopsies. Clinical translation will depend on standardized, transferable assays, external validation in representative populations, clearly defined contexts of use, and evidence that biomarker-guided strategies improve patient and allograft outcomes.

Current Opinion in Nephrology & Hypertension
Brigham and Women's Hospital (US), Albert Einstein College of Medicine (US), Montefiore Medical Center (US), Harvard University (US)
Good health and well-being
Renal Transplantation Outcomes and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon